Daniel Lippis Sells 619 Shares of Edwards Lifesciences (NYSE:EW) Stock

Key Points

• Edwards Lifesciences VP Daniel Lippis sold 619 shares for approximately $56,967 under a pre-arranged Rule 10b5-1 trading plan, reducing his ownership by 1.52% to 40,034 shares.
• Edwards Lifesciences shares rose 1.7% to $93.59, while the company’s latest quarterly results exceeded expectations: EPS was $0.78 versus a $0.74 consensus, and revenue increased 13.6% year over year to $1.74 billion.
• Analyst sentiment remains positive, with a “Moderate Buy” consensus and an average price target of $100.27; 79.46% of the stock is held by institutional investors and hedge funds.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 619 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares of the company's stock, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Up 1.7%

NYSE:EW traded up $1.56 during midday trading on Tuesday, reaching $93.59. 3,138,661 shares of the stock traded hands, compared to its average volume of 4,872,212. The stock has a market capitalization of $53.89 billion, a PE ratio of 53.79, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The business has a 50-day moving average of $88.38 and a two-hundred day moving average of $84.20.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the prior year, the business posted $0.67 EPS. The business's revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Institutional Trading of Edwards Lifesciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $25,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. MV Capital Management Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $26,000. RMG Wealth Management LLC purchased a new stake in Edwards Lifesciences during the first quarter worth $26,000. Finally, TrinityBridge Ltd acquired a new stake in Edwards Lifesciences during the second quarter valued at $27,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on EW. Barclays reaffirmed an "overweight" rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Truist Financial lifted their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a research report on Thursday, July 16th. Robert W. Baird boosted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a "neutral" rating in a research note on Friday, April 24th. Citigroup raised their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Finally, Leerink Partners raised Edwards Lifesciences from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $87.00 to $101.00 in a report on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source